The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Differential Activation of Signal Transduction Pathways in Human Hearts With Hypertrophy Versus Advanced Heart Failure
Abstract
Background —Left ventricular failure is commonly preceded by a period of hypertrophy. Intriguingly, many of the signaling pathways that have been implicated in the regulation of hypertrophy, including the 3 mitogen-activated protein kinases (MAPKs: extracellular signal-regulated kinase, stress-activated protein kinase, and p38), protein phosphatase, calcineurin, and the protein kinase Akt and its target glycogen synthase kinase-3 (GSK-3), also regulate the apoptotic response. Methods and Results —To understand the mechanisms that might regulate the progression of heart failure, we analyzed the activity of these signaling pathways in the hearts of patients with advanced heart failure, patients with compensated cardiac hypertrophy, and normal subjects. In patients with hypertrophy, neither the MAPK nor the Akt/GSK-3 pathways were activated, and the dominant signaling pathway was calcineurin. In failing hearts, calcineurin activity was increased but less so than in the hypertrophied hearts, and all 3 MAPKs and Akt were activated (and, accordingly, GSK-3β was inhibited), irrespective of whether the underlying diagnosis was ischemic or idiopathic cardiomyopathy. Conclusions —In the failing heart, there is a clear prohypertrophic activity profile, likely occurring in response to increased systolic wall stress and neurohormonal mediators. However, with the activation of these hypertrophic pathways, potent proapoptotic and antiapoptotic signals may also be generated. Therapies directed at altering the balance of activity of these signaling pathways could potentially alter the progression of heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Self-citationCa 2+ -Induced Apoptosis Through Calcineurin Dephosphorylation of BAD
Wang, H.-G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., & Reed, J. C. (1999) · Science · doi:10.1126/science.284.5412.339 · Cited by 1,132
Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway
Pap, M., & Cooper, G. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19929 · Cited by 1,040
Protein kinase cascades activated by stress and inflammatory cytokines
Kyriakis, J. M., & Avruch, J. (1996) · BioEssays · doi:10.1002/bies.950180708 · Cited by 709
Musarò, A., McCullagh, K. J. A., Naya, F. J., Olson, E. N., & Rosenthal, N. (1999) · Nature · doi:10.1038/23060 · Cited by 652
Protein Kinase B/Akt Participates in GLUT4 Translocation by Insulin in L6 Myoblasts
Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., & Klip, A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4008 · Cited by 592
Narula, J., Pandey, P., Arbustini, E., Haider, N., Narula, N., Kolodgie, F. D., Dal Bello, B., Semigran, M. J., Bielsa-Masdeu, A., Dec, G. W., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8144 · Cited by 585
Bowling, N., Walsh, R. A., Song, G., Estridge, T., Sandusky, G. E., Fouts, R. L., Mintze, K., Pickard, T., Roden, R., Bristow, M. R., et al. (1999) · Circulation · doi:10.1161/01.cir.99.3.384 · Cited by 457
Stress Pathways and Heart Failure
Chien, K. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80043-4 · Cited by 446
Cited by
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Hill, J. A., & Olson, E. N. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072139 · Cited by 1,065
Shiojima, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24682 · Cited by 939
Transcriptional control of mitochondrial biogenesis: the central role of PGC-1
Ventura-Clapier, R., Garnier, A., & Veksler, V. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn098 · Cited by 932
“Studies to determine the role of calcineurin in cardiac hypertrophy and heart failure have produced contradictory results, showing either calcineurin activation or no change or a decrease in calcineurin activity.(88,94) Despite the importance of CREB for transcriptional activation of PGC-1a, treating cardiac cells in…”
BackgroundResultBernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Physiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761
Self-citationTham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708
Protein kinase cascades in the regulation of cardiac hypertrophy
Dorn, G. W., & Force, T. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524178 · Cited by 638
Self-citationHorwich, T. B., Patel, J., MacLellan, W. R., & Fonarow, G. C. (2003) · Circulation · doi:10.1161/01.cir.0000084543.79097.34 · Cited by 590
Energy metabolism in heart failure
Ventura‐Clapier, R., Garnier, A., & Veksler, V. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055095 · Cited by 499
MOLKENTIN, J. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.01.021 · Cited by 497
Self-citationMAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets
Muslin, A. J. (2008) · Clinical Science · doi:10.1042/cs20070430 · Cited by 494
Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo
Antos, C. L., McKinsey, T. A., Frey, N., Kutschke, W., McAnally, J., Shelton, J. M., Richardson, J. A., Hill, J. A., & Olson, E. N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231619298 · Cited by 477
The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun
Sundaresan, N. R., Vasudevan, P., Zhong, L., Kim, G., Samant, S., Parekh, V., Pillai, V. B., Ravindra, P. V., Gupta, M., Jeevanandam, V., et al. (2012) · Nature Medicine · doi:10.1038/nm.2961 · Cited by 476
The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease
OUDIT, G. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.015 · Cited by 469
Signaling effectors underlying pathologic growth and remodeling of the heart
van Berlo, J. H., Maillet, M., & Molkentin, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62839 · Cited by 445
Self-citationGlycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
Garnier, A., Fortin, D., Deloménie, C., Momken, I., Veksler, V., & Ventura‐Clapier, R. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.045104 · Cited by 427
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy
Park, T.-S., Hu, Y., Noh, H.-L., Drosatos, K., Okajima, K., Buchanan, J., Tuinei, J., Homma, S., Jiang, X.-C., Abel, E. D., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800147-jlr200 · Cited by 411
Involvement of Extracellular Signal-Regulated Kinases 1/2 in Cardiac Hypertrophy and Cell Death
Bueno, O. F., & Molkentin, J. D. (2002) · Circulation Research · doi:10.1161/01.res.0000038488.38975.1a · Cited by 397
Self-citationEsposito, G., Rapacciuolo, A., Naga Prasad, S. V., Takaoka, H., Thomas, S. A., Koch, W. J., & Rockman, H. A. (2002) · Circulation · doi:10.1161/hc0102.101365 · Cited by 377
Mechanisms of Altered Ca 2+ Handling in Heart Failure
Luo, M., & Anderson, M. E. (2013) · Circulation Research · doi:10.1161/circresaha.113.301651 · Cited by 357
WNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-139634 · Cited by 335
Calcium, Calmodulin, and Calcium-Calmodulin Kinase II: Heartbeat to Heartbeat and Beyond
Maier, L. S., & Bers, D. M. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2038 · Cited by 309
Muchir, A., Pavlidis, P., Decostre, V., Herron, A. J., Arimura, T., Bonne, G., & Worman, H. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29042 · Cited by 309
17β-Estradiol Attenuates the Development of Pressure-Overload Hypertrophy
van Eickels, M., Grohé, C., Cleutjens, J. P. M., Janssen, B. J., Wellens, H. J. J., & Doevendans, P. A. (2001) · Circulation · doi:10.1161/hc3601.095577 · Cited by 300
Calmodulin-Dependent Protein Kinase II: Linking Heart Failure and Arrhythmias
Swaminathan, P. D., Purohit, A., Hund, T. J., & Anderson, M. E. (2012) · Circulation Research · doi:10.1161/circresaha.111.243956 · Cited by 283
Judging a Protein by More Than Its Name: GSK-3
Woodgett, J. R. (2001) · Science's STKE · doi:10.1126/stke.2001.100.re12 · Cited by 279
MATSUI, T., & ROSENZWEIG, A. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.11.005 · Cited by 261
Pepe, M., Mamdani, M., Zentilin, L., Csiszar, A., Qanud, K., Zacchigna, S., Ungvari, Z., Puligadda, U., Moimas, S., Xu, X., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.220855 · Cited by 93
Kinugawa, K., Jeong, M. Y., Bristow, M. R., & Long, C. S. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0503 · Cited by 80
Bhushan, S., Kondo, K., Polhemus, D. J., Otsuka, H., Nicholson, C. K., Tao, Y.-X., Huang, H., Georgiopoulou, V. V., Murohara, T., Calvert, J. W., et al. (2014) · Circulation Research · doi:10.1161/circresaha.114.301475 · Cited by 69
Wnt/β-catenin pathway in arrhythmogenic cardiomyopathy
Lorenzon, A., Calore, M., Poloni, G., De Windt, L. J., Braghetta, P., & Rampazzo, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17457 · Cited by 64
Wang, S.-B., Venkatraman, V., Crowgey, E. L., Liu, T., Fu, Z., Holewinski, R., Ranek, M., Kass, D. A., O’Rourke, B., & Van Eyk, J. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.312789 · Cited by 54
Suarez, J., Scott, B. T., Suarez-Ramirez, J. A., Chavira, C. V., & Dillmann, W. H. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00168.2010 · Cited by 30
Metadata
- Authors
- Haq, S., Choukroun, G., Lim, H., Tymitz, K. M., del Monte, F., Gwathmey, J., Grazette, L., Michael, A., Hajjar, R., Force, T., & Molkentin, J. D.
- Venue
- Circulation
- Published
- 2001-02-06
- Volume
- 103
- Issue
- 5
- Pages
- 670-677
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1989950796
- Cited by
- 440
- References
- 20
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.